Clopidogrel Response in Acute Ischemic Stroke
Completed
- Conditions
- Ischemic Stroke
- Registration Number
- NCT01846572
- Lead Sponsor
- Ruhr University of Bochum
- Brief Summary
The aim of this study was to determine the prevalence rate and risk factors for chemical laboratory clopidogrel low-response (CLR) in the acute phase after an ischemic stroke.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 159
Inclusion Criteria
- acute ischemic stroke
- admittance to stroke unit
- clopidogrel medication
Exclusion Criteria
- no consent
- prior bleeding disorders
- severe liver disorders
- current gastrointestinal disorders
- congestive heart failure
- life-threatening malignancies
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Result of platelet function test 1 day Aggregometry result of antiplatelet therapy
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie clopidogrel low-response (CLR) in acute ischemic stroke patients as studied in NCT01846572?
How does clopidogrel's efficacy in preventing ischemic stroke recurrence compare to standard-of-care antiplatelet therapies in observational studies?
Which biomarkers are associated with clopidogrel resistance in ischemic stroke populations, and how do they correlate with outcomes in NCT01846572?
What adverse events are reported in clopidogrel-treated acute ischemic stroke patients, and how are they managed in clinical practice?
How do alternative P2Y12 inhibitors like prasugrel or ticagrelor compare to clopidogrel in acute ischemic stroke management based on pharmacogenomic data?